Search
for
Sort by
Research 751–780 of 1000+
- Targeting PrfA from Listeria monocytogenes: a computational drug repurposing approach
- Androgenic alopecia updates
- Saç Dökülmesi
- Managing patterned hair loss – a hair raising task!
- Synthetic Hairs: Their Role in Hair Restoration
- Arterielles popliteales Entrapment Syndrom (PAES) — ein Fallbericht zur Differentialdiagnose der Claudicatio intermittens
- Update Treatment of Male Androgenetic Alopecia
- Androgenetic Alopecia in Adolescents
- Male Androgenetic Alopecia — Endotext
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- JAK Inhibitors for Treatment of Alopecia Areata
- Pediatric Systemic Lupus Erythematosus: More Than a Positive Antinuclear Antibody
- Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- Mesotherapy for local fat reduction
- Spironolactone for treatment of female pattern hair loss
- Physiology and Medical Treatments for Alopecia
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Androgenetic alopecia – Current status
- Highlights of Gene and Cell Therapy for Epidermolysis Bullosa and Ichthyosis
- The inflammatory component of androgenetic alopecia
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies
- Polycystic Ovary Syndrome
- Hyperammonemia with Valproic Acid: Colonic Ischemia Associated with “Triptan” Use Visual Side Effects with Pegylated Interferon: Alopecia Areata with Infliximab: Adverse Effects Seen with Medications Used for Irritable Bowel Syndrome
- DKK1-targeting cholesterol-modified siRNA implication in hair growth regulation
- Unknown safety profile of ingredients in hair supplements: A call to action for improved patient safety
- 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
- Clinical Trials and Hair Loss